ClinActis

Executive Summary

ClinActis is a Singapore-based full-service contract research organization (CRO) specializing in end-to-end clinical trial management across the Asia-Pacific region. Founded in 2009, the company has grown to employ 200–500 staff and leverages a senior team with over 50 years of combined experience. Its extensive network of more than 500 clinical sites and deep local regulatory knowledge across over a dozen APAC markets positions it as a key partner for biotech, pharma, medical-device, and medical-nutrition sponsors. ClinActis offers a comprehensive suite of services including study design, regulatory submissions, monitoring, data management, and medical writing, enabling sponsors to efficiently navigate the complex APAC regulatory landscape and accelerate trial timelines. As a private, independently funded CRO, ClinActis remains focused on organic growth and strengthening its service capabilities. The company’s competitive edge lies in its ability to provide seamless, high-quality clinical trial execution in diverse APAC markets, which are increasingly attractive for global drug development due to large patient pools and cost efficiencies. While specific financials are undisclosed, ClinActis’s established track record and operational scale suggest a stable foothold in the region. Key upcoming catalysts may include further expansion of its site network, new strategic partnerships with biopharma firms, and recognition through regulatory approvals or awards that enhance its credibility as a preferred CRO in Asia-Pacific.

Upcoming Catalysts (preview)

• Q4 2026Expansion into new APAC markets or therapeutic areas70% success
• Q2 2027Major strategic partnership with a top-20 pharma company40% success
• Q3 2026Award or accreditation from a regulatory body (e.g., Singapore HSA)60% success